These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35395808)

  • 1. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
    Schnell O; Battelino T; Bergenstal R; Blüher M; Böhm M; Brosius F; Carr RD; Ceriello A; Forst T; Giorgino F; Guerci B; Heerspink HJL; Itzhak B; Ji L; Kosiborod M; Lalić N; Lehrke M; Marx N; Nauck M; Rodbard HW; Rosano GMC; Rossing P; Rydén L; Santilli F; Schumm-Draeger PM; Vandvik PO; Vilsbøll T; Wanner C; Wysham C; Standl E
    Cardiovasc Diabetol; 2022 Apr; 21(1):50. PubMed ID: 35395808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.
    Schnell O; Battelino T; Bergenstal R; Birkenfeld AL; Ceriello A; Cheng A; Davies M; Edelman S; Forst T; Giorgino F; Green J; Groop PH; Hadjadj S; J L Heerspink H; Hompesch M; Izthak B; Ji L; Kanumilli N; Mankovsky B; Mathieu C; Miszon M; Mustafa R; Nauck M; Pecoits-Filho R; Pettus J; Ranta K; Rodbard HW; Rossing P; Ryden L; Schumm-Draeger PM; Solomon SD; Škrha J; Topsever P; Vilsbøll T; Wilding J; Standl E
    Cardiovasc Diabetol; 2023 Mar; 22(1):59. PubMed ID: 36927451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.
    Schnell O; Cos X; Cosentino F; Forst T; Giorgino F; Heersprink HJL; Kosiborod M; Wanner C; Standl E
    Cardiovasc Diabetol; 2021 Mar; 20(1):75. PubMed ID: 33789663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report from the 5th cardiovascular outcome trial (CVOT) summit.
    Schnell O; Standl E; Cos X; Heerspink HJ; Itzhak B; Lalic N; Nauck M; Ceriello A
    Cardiovasc Diabetol; 2020 Apr; 19(1):47. PubMed ID: 32303223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Itzhak B; Lalic N; Rahelic D; Skrha J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2019 Mar; 18(1):30. PubMed ID: 30857522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Skra J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2016 Feb; 15():33. PubMed ID: 26892706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Lalic K; Skrha J; Valensi P; Ceriello A
    Cardiovasc Diabetol; 2018 Feb; 17(1):30. PubMed ID: 29458368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.
    Schnell O; Standl E; Catrinoiu D; Genovese S; Lalic N; Skra J; Valensi P; Rahelic D; Ceriello A
    Cardiovasc Diabetol; 2017 Mar; 16(1):35. PubMed ID: 28284218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of cardiovascular outcomes trials of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    North EJ; Newman JD
    Curr Opin Cardiol; 2019 Nov; 34(6):687-692. PubMed ID: 31436559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review.
    Honigberg MC; Chang LS; McGuire DK; Plutzky J; Aroda VR; Vaduganathan M
    JAMA Cardiol; 2020 Oct; 5(10):1182-1190. PubMed ID: 32584928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
    Hupfeld C; Mudaliar S
    Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Outcome Trials with Glucose-Lowering Drugs.
    Thethi TK; Bilal A; Pratley RE
    Curr Cardiol Rep; 2021 Jun; 23(7):75. PubMed ID: 34081215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
    Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
    Ludwig L; Darmon P; Guerci B
    Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors: practical considerations and recommendations for cardiologists.
    Opingari E; Partridge ACR; Verma S; Bajaj HS
    Curr Opin Cardiol; 2018 Nov; 33(6):676-682. PubMed ID: 30148719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.